Skip to content
PeptideAgent

Peptides for tendon repair: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Tendon injuries heal slowly because tendon tissue has low blood supply and cell turnover. BPC-157 and TB-500 are the most searched peptides for tendon healing, but every supporting study is in rodents; no randomized human trial has been published for either.

Evidence: Strongest: Animal-only evidence3 peptides gradedVerified: Verified Sep 23, 2026

Do peptides help with tendon injury and tendinopathy?

3 peptides are graded for tendon injury and tendinopathy on this page. The strongest grade is animal-only evidence, for BPC-157, TB-500 (thymosin beta-4), and GHK-Cu. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for tendon injury and tendinopathy?

Progressive loading and eccentric exercise, activity modification, and time; short courses of NSAIDs for pain; physical therapy. Corticosteroid injection gives short term relief but can weaken tendon. Platelet rich plasma and surgery are considered for refractory cases.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for tendon injury and tendinopathy?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Tendon injury and tendinopathy with evidence grades
PeptideEvidence for this useNote
BPC-157Evidence: Animal-only evidenceFaster Achilles tendon healing and increased tendon cell outgrowth in rats; no human RCT. [1] [2]
TB-500 (thymosin beta-4)Evidence: Animal-only evidenceCell migration and wound closure effects in animal and cell models; no human RCT for tendon injury. [3]
GHK-CuEvidence: Animal-only evidenceCollagen synthesis and remodeling effects in animal and cell models; human data limited to skin. [4]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Do peptides help tendon repair?

Not in any published human trial. BPC-157 sped Achilles tendon healing in rats, and TB-500 and GHK-Cu show tissue repair effects in animal and cell models, but none has a randomized human trial for tendon injury. [1] [2] [3] [4]

Is any peptide FDA approved for tendon injury and tendinopathy?

No. None of the peptides graded for tendon injury and tendinopathy is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [5]

Has any peptide been tested in a randomized trial for tendon injury and tendinopathy?

No. The best evidence for any peptide graded for tendon injury and tendinopathy is animal only evidence, so none has been shown to work in a randomized human trial for this use. [1] [2] [3] [4]

Is BPC-157 legal?

BPC-157 is not an FDA approved drug. FDA removed it from the 503A Category 2 safety list in April 2026, and its compounding advisory committee recommended it for the 503A bulks list in July 2026, but that vote is advisory. Until FDA publishes a final rule, a 503A pharmacy has no federal basis to compound BPC-157 from bulk. [6] [7]

From the blog

Sources

  1. [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing (J Appl Physiol 2011)PubMed 21030672, 2011
  2. [2]BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
  3. [3]Thymosin beta4 accelerates wound healingPubMed 10469335, 1999
  4. [4]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene dataPubMed 29986520, 2018
  5. [5]Drugs@FDA: FDA-approved drugs databaseFDA
  6. [6]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  7. [7]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026